Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK-positive Non Small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07491497
What this trial is testing

TRI-611 in ALK-Positive NSCLC

Who this might be right for
ALK-positive NSCLCALK-Positive Lung CancerALK-positive Non-small Cell Lung Cancer
TRIANA Biomedicines, Inc. 160
Not applicableUnknownNCT06410040
What this trial is testing

A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis

Who this might be right for
ALK-positive Non-small Cell Lung CancerBrain MetastasesMeningeal Metastasis
Sichuan Cancer Hospital and Research Institute 28
Post-approval studies (Phase 4)Ended earlyNCT03672643
What this trial is testing

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

Who this might be right for
ALK or ROS1-positive NSCLC
Pfizer 41
Not applicableActive Not RecruitingNCT07556549
What this trial is testing

Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

Who this might be right for
Non-Small Cell Lung Cancer ALK-positive
Pfizer 50
Testing effectiveness (Phase 2)WithdrawnNCT05948462
What this trial is testing

Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib

Who this might be right for
Lung CancerNon-small Cell Lung Cancer
SCRI Development Innovations, LLC
Not applicableNo Longer AvailableNCT05100134
What this trial is testing

Managed Access Programs for LDK378, Ceritinib

Who this might be right for
Anaplastic Lymphoma Kinase (ALK)- Positive TumorsNon-small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals
Not applicableLooking for participantsNCT05122806
What this trial is testing

Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

Who this might be right for
Non-small Cell Lung CancerALK Gene Rearrangement Positive
Groupe Francais De Pneumo-Cancerologie 100
Early research (Phase 1)Study completedNCT02422589
What this trial is testing

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

Who this might be right for
ALK-positive Advanced Tumors
Novartis Pharmaceuticals 33
Post-approval studies (Phase 4)Active Not RecruitingNCT05144997
What this trial is testing

Lorlatinib Continuation Study

Who this might be right for
Non-Small-Cell Lung CancerNSCLC
Pfizer 76
Testing effectiveness (Phase 2)UnknownNCT05257512
What this trial is testing

Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Shouyao Holdings (Beijing) Co. LTD 150
Large-scale testing (Phase 3)Active Not RecruitingNCT02767804
What this trial is testing

EXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Non-small Cell Lung Cancer
Xcovery Holdings, Inc. 290
Early research (Phase 1)Active Not RecruitingNCT05441956
What this trial is testing

TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
Shenzhen TargetRx Co., Ltd. 198
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine 156
Not applicableActive Not RecruitingNCT07567352
What this trial is testing

Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

Who this might be right for
Non-Small-Cell LungALK-positive Advanced NSCLCALK-positive Non-small-cell Lung Cancer+1 more
Pfizer 200
Testing effectiveness (Phase 2)Ended earlyNCT03131206
What this trial is testing

Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Who this might be right for
ALK-positive Non-small Cell Lung Cancer (NSCLC)RET-positive Non-small Cell Lung Cancer (NSCLC)RET-positive Thyroid Cancer
Dana-Farber Cancer Institute 5
Testing effectiveness (Phase 2)Looking for participantsNCT07415005
What this trial is testing

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center 30
Not applicableLooking for participantsNCT06862869
What this trial is testing

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 800
Post-approval studies (Phase 4)Study completedNCT04362072
What this trial is testing

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

Who this might be right for
CarcinomaNon-Small-Cell Lung
Pfizer 71
Testing effectiveness (Phase 2)Ended earlyNCT02513667
What this trial is testing

Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma

Who this might be right for
ALK-positive Non-small Cell Lung Cancer
University of Texas Southwestern Medical Center 14
Large-scale testing (Phase 3)Study completedNCT03596866
What this trial is testing

Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

Who this might be right for
ALK+ Advanced NSCLC
Takeda 248
Next Page